VCEL (Vericel Corporation) Short-Term Debt to Capital

Corporate company logo of Vericel Corporation (VCEL)

Vericel Corporation (VCEL) is developing cellular restoration methods for skin and cartilage, utilizing two marketed products to ensure revenue stability. The price action vector available for analysis on GURU.Markets with the 0.05 indicator confirms the potential of this regenerative medicine. Vericel Corporation (VCEL) creates tissues from a patient's own cells by implementing advanced engineering. The business is currently scaling sales by expanding its sales representative workforce across the United States.

Ratio of Short-Term Indebtedness to Capital: Vericel Corp. (VCEL) for 07/04/2022 - 10/31/2026

Analytical breakdowns for Vericel Corporation

- stock quotes and analyst forecast:
Stock Price Vericel Corp.|VCEL - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Vericel Corp|VCEL - Enterprise Value
- book capitalization information:
Net Assets per Single Share Vericel|VCEL - Accounting Value of Company|Market Value to Book Value Ratio vcel.com|VCEL - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Vericel Corporation|VCEL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Vericel|VCEL - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Vericel Corp|VCEL - Long-Term Debt Volume|Company Short-Term Debt Vericel|Quick Ratio vcel.com
- company profitability and valuation multiples indicators:
VCEL - Net Financial Result
Fundamental valuation:VCEL Vericel Corp.
Brand item of Vericel Corp

Steady sales growth of cellular products and management discipline at Vericel Corporation (VCEL) enable effective control of the current debt load. By analyzing the ratio of short-term liabilities to equity, an investor assesses the share of short-term loans within the equity structure, where a decrease in this metric confirms growing financial autonomy and an expanded margin of safety for the company's assets.

Main competitors

Short-Term Debt to Capital KRYS|APGE (Apogee Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ARQT (Arcutis Biotherapeutics)|Short-Term Debt to Capital orukatx.com ORKA|SMTI - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital DBVT (DBV Technologies S.A.)|solesence.com (SLSN) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio Journey Medical Corporation|FBRX (Forte Biosciences, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital empro.my|Short-Term Debt to Equity Ratio SLGL (Sol-Gel Technologies Ltd.)|AXIL (reviveprocare.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Medicus Pharma Limited MDCX|Short-Term Debt to Capital Coefficient Verrica Pharmaceuticals Inc (VRCA)|HOTH - Short-Term Debt to Equity|BFRI - Short-Term Debt to Capital|VYNE: Short-Term Debt to Capital|SNOA - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Quoin Pharmaceuticals Ltd|Short-Term Debt to Capital Ratio AZTR (Azitra Corporation)|Short-Term Debt to Equity Ratio DRMA (Dermata Therapeutics)|Short-Term Debt to Equity ELAB (elevaiskincare.com)|Short-Term Debt to Capital RVNC (Revance Therapeutics, Inc.)